Claresa Levetan
Wynnewood, PA (USA)
Role(s):
CureDM
Find More Startups
Startup
Location:
Wynnewood
Industry:
Healthcare
Year Founded:
2008
Number Employees:
INVALID
Description:
The CureDM approach to restore new insulin-producing cells through islet neogenesis can potentially reverse both type 1 and type 2 diabetes. Our lead compound, Human proIslet Peptide (HIP)Human proIslet Peptide (HIP) stimulates the differentiation of pancreatic progenitor cells, which are present in the adult pancreas, into new insulin-producing islets. Each new islet contains pools of beta cells which make insulin. It is hypothesized that treatment with this therapeutic will restore human pancreatic function without the use of stem cells. Patients with type 1 diabetes will require pretreatment with an immune tolerance agent to protect new islets formed by HIP.
Human proIslet Peptide (HIP) stimulates the differentiation of pancreatic progenitor cells, which are present in the adult